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Introduction
Chronic joint disorders represent some of the most
prevalent pain conditions treated in primary care (Carmona
et al 2001, Mantyselka et al 2001). They constitute several
entities, with the common factor that pain is located at the
articular structures. 
Osteoarthritis is probably the most common entity and the
prevalence of osteoarthritis is rising parallel to the
increasing age of the population (Felson et al 2000).
Temporomandibular joint disorders, patellofemoral pain
syndrome and mechanical spine disorders are other
examples of chronic joint disorders. These conditions can
be associated with impaired muscular stabilisation (Cowan
et al 2001, Radebold et al 2001), reduced range of motion
(McNamara et al 1996, Steultjens et al 2000) and
inflammation of the joint capsule (Speldewinde et al 2001,
Suenaga et al 2001, Vaatainen et al 1998). 
A link has been established between synovial inflammatory
activity and worsening of cartilage degeneration in
osteoarthritis (Chikanza and Fernandes 2000). In this
context, it is interesting to investigate if an anti-
inflammatory action can be induced clinically by
electrophysical agents. 
Controlled laboratory trials have found that LLLT can
reduce inflammation through reduction of PGE
2
-levels and
inhibition of cyclooxygenase-2 (COX-2) in cell cultures
(Campaña et al 1993, Honmura et al 1993, Sakurai et al
2000, Shimizu et al 1995). The transformation of
encouraging laboratory results into clinical effectiveness
has been a difficult task (Basford 1995), and clinical
effectiveness of LLLT has been questioned in systematic
reviews on a broad range of conditions (de Bie et al 1998,
Del Mar et al 2001, Gam et al 1993). A recent Cochrane
systematic review on LLLT found a minor positive effect
on rheumatoid arthritis, but the material on osteoarthritis
was conflicting (Brosseau et al 2000). In the following
review, our hypothesis is that laser irradiation of the joint
capsule can reduce pain in chronic joint disorders if the
dose is adjusted to inhibit inflammatory activity in the joint
capsule.
Materials and methods  A detailed review protocol was
specified prior to conducting the review. This included a
sequential four-step reviewing procedure involving
predetermination of an optimal dose range, conduct of a
sensitive literature search, application of a pre-specified
inclusion/exclusion procedure, and testing of differences
between trials with and without optimal dose. 
The optimal dose range was derived from successful
laboratory trials prior to the literature search. In the first
step of the reviewing procedure, an optimal dose range was
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determined at the target location and then adjusted
according to energy loss estimates for each anatomical
location and the size of affected peripheral, facial and
spinal joints. 
Determination of possible anti-inflammatory LLLT dose
at target location In in vitro trials, LLLT has been reported
to suppress inflammation by a reduction of PGE
2 
in
ligament cell cultures (Sakurai et al 2000, Sattayut et al
1999, Shimizu et al 1995). Low level laser therapy has also
been found to reduce PGE
2
levels in the joint capsule of
animals in in vivo trials (Campaña et al 1993 and 1999,
Honmura et al 1993, Sakurai et al 2000) . This effect was
reported within a range between 0.4 and 19 J and a power
density of 5-21.2 mW/cm2. The lower range limits for PGE
2
reduction were identified because data showed no effect
below this threshold. Upper range limits could not be
identified, as there were no data available to show when or
if this effect would level off. However, it has been shown
that power densities above 20 mW/cm2 temporarily inhibit
fibroblast metabolism (van Breugel and Bar 1992), and
numerous fibroblast cells are found in the joint capsule. We
assumed doses of 0.4-19 J and power density of 5-21
mW/cm2  would be capable of reducing inflammation at the
target joint capsule without compromising fibroblast
metabolism.
Location-specific dose adjustment for energy loss and
anatomical size Data on beam diameter and laser output
were collected from the manufacturers’ manuals. Power
density and dose were calculated according to the
following formulas: 
Power density for GaAs 904 nm pulse lasers (mW/cm2) =
(peak power pulse x pulse duration x pulses frequency)
/spot size on skin.
Power density for lasers with continuous output (mW/cm2)
= mean power/spot size on skin.
Dose (J) = mean power x treatment time per session.
Measurement of light penetration and absorption in
biological tissue is dependent on several variables. Two
anatomical factors are essential to LLLT dose calculations:
distance from skin to synovia and size (area) of the affected
synovia. For knee (anteromedial and anterolateral part),
finger, toe and temporomandibular joint, the distance from
skin ranges from 1.5 to 5 mm (authors’ unpublished data;
10 persons scanned by 7.5 MHz ultrasound imaging). The
distance from skin surface to the zygapophyseal joints was
8 to 20 mm for the cervical spine and 25-35 mm for the
lumbar spine. Another variable that affects penetration is
the wavelength of the laser. Infrared laser light has been
demonstrated to have a typical penetration depth (ie the
distance which reduces the incident energy to 37%) of
nearly 3 mm, while red laser light has a penetration depth
of 1 mm (Kolari and Airaksinen 1988). Although energy
loss is exponential near the laser source, optical
measurements have demonstrated that energy loss is nearly
linear at greater distances (Faris et al 1991). In an
experimental porcine tongue model, a 200 mW GaAlAs
laser had intensity reduced to 16 mW after the first 15 mm,
which is within our suggested optimal dose range (Bradley
et al 1998, Gursoy and Bradley 1994). From this depth,
intensities fell at a slower almost linear rate to 1.4 mW at
35 mm. In vivo trials with 904 nm pulse lasers have
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Table 1. Suggested range of power densities and dose for the most common joints for infrared GaAlAs and Nd:YAG
(continuous) lasers with wavelength 820, 830 and 1060 nm; infrared GaAs (pulse) lasers with wavelength 904 nm; and red
HeNe (continuous) lasers with wavelength 632 nm.
IR 820, 830, 1060 nm IR 904 nm HeNe 632 nm
Location Power density Dose Power density Dose Power density Dose 
(mW/cm2) (Joules) (mW/cm2) (Joules) (mW/cm2) (Joules)
Finger/toe/ 15 - 105 0.5 - 15 6 - 42 0.2 - 1.4 30 - 210 6 - 30
temporomandibular
1 point/1 cm2
Depth 2 mm
Knee 30 - 210 6 - 180 12 - 60 1.2 - 84 90 - 500 9 - 2700
3 points/3 cm2
Depth 4 mm
Cervical spine 50 - 350 11 - 360 24 - 60 0.8 - 56 150 - 500 5 - 150
3 points/3 cm2
Depth 12 mm
Lumbar spine 180 - 500 48 - 480 30 - 210 15 - 105 Not applicable Not applicable
3 points/3 cm2 as optimal power
Depth 30 mm density is above 
safety regulations 
for laser
demonstrated that these lasers achieve similar effects on
collagen production with far lower doses on the animals’
skin than lasers with continuous output (Enwemeka 1991,
van der Veen and Lievens 2000). This effect can be
attributed to the photobleaching phenomenon, where the
first strong pulse bleaches the opaque barrier of tissue,
letting the second pulse pass through the tissue barrier with
less loss of energy (Kusnetzow et al 2001).
We postulate that energy loss due to the skin barrier for
continuous HeNe (632nm) laser is 90%, for continuous
GaAlAs (820nm) and NdYag IR lasers, 80% and for GaAs
(904 nm) infrared pulse laser, 50%. Further energy loss is,
according to the porcine penetration model, postulated to
be linear at 5% per mm of tissue for infrared lasers. For red
HeNe laser we postulate that further energy loss is 10% per
mm of tissue.
The synovial area is rather small in finger, toe and
temporomandibular joints, and we postulate that at least
one single point is necessary to deliver an optimal dose of
LLLT in these locations. We also postulate that a minimum
of three points of the synovial membranes of the knee and
the zygapaphyseal joints of the spine must be irradiated to
provide a sufficient dose for these locations.
Estimations of dose and power densities required for the
different anatomical locations are shown in Table 1. 
Literature search A pre-specified literature search was
performed from 1980 through to November 2001 on
MEDLINE, Embase, CINAHL, PEDro and the Cochrane
Controlled Trials Register (Central) for randomised
controlled clinical trials.
Key words were: Low level laser therapy, low intensity
laser therapy, low energy laser therapy, HeNe laser, IR
laser, GaAlAs, GaAs, diode laser, osteoarthritis, chronic
joint disorder, temporomandibular joint, hip, knee, thumb,
spine. Hand searching was also performed on national
physiotherapy and medical journals from Norway,
Denmark, Sweden, The Netherlands, Germany,
Switzerland, England, USA, Canada and Australia.
Additional information on randomised controlled trials was
gathered from researchers in the field. The literature search
was concluded by the end of November 2001.
Methods
Inclusion criteria The trials were subjected to six
inclusion criteria: joint disorder of more than six months
duration or osteoarthritis verified by x-ray, random
allocation of patients to groups, control group received
identical placebo treatment, blind patients and outcome
assessors, laser exposure of skin overlying inflammatory
joint capsule, and outcome measure of pain and change in
health status.
Assessment of methodological quality A criteria list of 10
methodological criteria developed for the PEDro database
of physiotherapy trials at The University of Sydney,
Australia, was used (Moseley et al 2002). Assessments of
methodology were made by an assessor who was blinded to
the trial results. No specific cut-off limit for method scores
was pre-planned as a criterion for exclusion.
Outcome measures We selected pain on a visual analogue
scale (VAS) as the first of two main outcome measures. In
trials where several aspects of pain were measured,
measures of pain during physical activity were preferred.
Variance was calculated from post-treatment data and
given as 95% confidence intervals (95% CI) in millimetres
on VAS. Results were presented as weighted mean
differences (WMD), ie a pooled estimate of the difference
in mean change of the treatment and the placebo groups
weighted by the inverse of the variance using a random
effects model. Variance was calculated from the standard
deviation (SD) of post-treatment data and given as 95%
CIs. If variance data were reported as interquartiles, then
the average SD from the other included trials was used for
the statistical pooling.
The second main outcome measure was categorical data of
change in global health status. Improved global health
status was defined as any one of the following categories:
“improved”, “good”, “better”, “much improved”, “pain-
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Table 2. List of excluded studies.
Author Joint (s) Result Reason for exclusion
Gallachi 1981 Cervical and lumbar No significant differences Acupuncture and trigger point exposure only
Lewith 1981 Knee LLLT significantly better Trigger point exposure only
than placebo 
Walker 1983 Not stated LLLT significantly better Peripheral nerve exposure only, randomisation
than placebo doubtful 
Waylonis 1988 Low back No significant differences Trigger point exposure only
Snyder-Mackler 1989 Lumbar and cervical LLLT significantly better Trigger point exposure only
than placebo
Rogvi-Hansen 1991 Knee No significant differences Did not irradiate joint, but peripheral nerves 
and top of patella only
free”, “excellent”. If sufficient data from the trial reports
were provided, then the proportions of “improved” and “not
improved” patients were pooled and expressed as a relative
risk. A random effects model was used for statistical
pooling.
Results
Included studies The literature search identified 88
randomised controlled trials of LLLT, of which 20 included
chronic joint disorders. Six trials were excluded for not
irradiating the skin directly overlying the joint capsule
(Gallachi et al 1981, Lewith and Machin 1981, Rogvi
Hansen et al 1991, Snyder-Mackler et al 1989, Walker
1983, Waylonis et al 1988) (Table 2).
A total of 14 trials with 695 patients (Basford et al 1987
and 1999, Bertolucci and Grey 1995, Bulow et al 1994,
Conti 1997, Gray et al 1994, Götte et al 1995, Jensen et al
1987, Klein and Eek 1990, Nivbrant and Friberg 1992,
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Table 3. List of included trials with treatment specifications.
First author Location Laser Laser Power Dose No. of Co-
and year of type, continuous density (Joule) sessions/ interventions
publication manufacturer output (mW/cm2) sessions
(maximum per week
pulse) and 
treatment time
Basford 1987 Thumb 632 nm (P) 0.4 mW 90 0.0135* 9/3 Drugs 
Dynatronics 1 min registered
Jensen 1987 Knee 904nm (P) 0.3 mW*(2W) 0.3 0.05* 5/5 Analgesics 
Space CEB (200 Hz) 6 min registered
Klein 1990 Lumbar 904 nm (P) 0.4mW* (2W) 0.4 0.1 * 8/2 Exercises
spine Physio 4 min NSAIDs 
Technology
Stelian 1991 Knee 630 nm (P) 75 mW 34 10.3 20/10 Analgesics
820 nm (P) 25 mW 11 11.1 
Amcor 15 min
Nivbrant 1992 Knee 904 nm (P) 4 mW(10 W) 57 2.1 6/3 Analgesics 
ASA 5000 Hz, registered, 
3 min  (C) NSAIDs not 
allowed
Bulow 1994 Knee 830 nm (P) 25 mW 110 22.5 9/3 Drugs 
Unilaser 15 min (C) registered
Gray 1994 TMJ 904 nm (P) 4 mW(27 W)* 57 0.7* 12/3 Not registered
Space CEB 3 min
Toya 1994 Lumbar 830 nm (P) 60 mW 3000 48-60 1/1 Not allowed
Cervical OhLase3D1 9 min
Extremity
Bertolucci 1995 TMJ 904 nm ASA 4 mW (10W) 57 2.1 9/3 Not registered
(700 Hz)  9 min
Gøtte 1995 Knee 904 nm Felas 12 mW (25W) 4 12* 12/3 NSAIDs not 
13 min allowed
Conti 1997 TMJ 830 nm (P) 100mW 38887 4 4/1 Not registered
Omnilase 40 sec
Soriano 1998 Lumbar 904 nm (P) 40 mW 40 16* 10/5 NSAIDs and
spine Brand missing (20W)10 kHz physiotherapy 
not allowed
Basford 1999 Lumbar NdYag 1626 mW, 542 48.8 12/3 NSAIDs allowed
spine Laser Biotherapy 6 min (C)
Özdemir 2001 Cervical 830 nm (P) 50 mW 390 10.8 10/7 Not registered
spine Enraf Nonius 3 min
Trials with dose or power density outside suggested range in Italics. NSAID, non-steroidal anti-inflammatory drug; P,
pointer; *, dose revised by reviewers; TMJ, temporomandibular joint.
Özdemir et al 2001, Soriano and Rios 1998, Stelian et al
1992, Toya et al 1994) satisfied our inclusion criteria. A list
of included trials and their treatment characteristics is
summarised in Table 3.
Dose assessment The results of the dose assessment
revealed that three trials (Basford et al 1987, Jensen et al
1987 and Klein and Eek 1990) did not use doses inside our
dose suggested range. These trials are indicated in Italics in
Table 3. The remaining 11 trials, which included 565
patients, adhered to the suggested dose range. 
Method scoring Method scores for trials that used the
suggested dose range satisfied on average 6.9 out of 10
possible criteria on the PEDro scale, while the remaining
three trials satisfied six out of all 10 criteria on the PEDro
scale. Seven trials had previously been assessed by PEDro
reviewers. For one trial, our assessment differed from the
PEDro database scores (Jensen et al 1987). Missing
concealed allocation to groups and intention to treat
analysis were the most frequent shortcomings in the
included trials. The results of the method scoring is
summarised in Table 4.
Pain reduction on VAS Nine trials provided data of pain on
VAS (Table 5). Two trials used a dose outside our suggested
dose range and both reported a non-significant difference in
pain reduction (Conti 1997, Klein and Eek 1990). Of the
remaining eight trials with LLLT dose inside our suggested
dose range, one trial reported variance data as interquartiles
(Bulow et al 1994). These variance data were substituted by
the average SD of the other six trials in the statistical
pooling. By using a random effects model, WMD in change
of pain on a 100 mm VAS was calculated to 29.8 mm (95%
CI 18.9 to 40.7) in favour of active laser (Figure 1).
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Table 4. Method scores (PEDro scale).
First author Random- Concealed Baseline Patient Therapist Observer With- Intention- Between- Mean Total
isation allocation similarity blinded blinded blinded drawals/ to-treat- groups and score
performed to groups dropouts analysis difference variability
< 15% tested data
statistically
Basford 1987 1 0 1 1 1 1 1 0 1 1 8*
Jensen 1987 1 0 0 1 (0) 0 1 (0) 1 0 1 0 5(3*)
Klein 1990 1 0 1 1 1 1 0 0 1 1 7*
Stelian 1991 1 0 1 1 1 1 1 0 1 1 8
Nivbrant 1992 1 0 1 1 1 1 1 0 0 1 7
Bulow 1994 1 0 0 1 1 0 1 0 1 1 6
Gray 1994 1 0 0 0 1 1 0 0 1 1 5*
Toya 1994 1 1 1 1 1 1 1 0 1 1 9*
Bertolucci 1995 1 0 0 1 1 0 1 0 1 1 6
Gøtte 1995 1 0 1 1 0 1 1 0 1 1 7
Conti 1997 1 0 1 1 0 1 1 1 0 0 6
Soriano 1998 1 0 1 1 1 1 0 0 1 1 7*
Basford 1999 1 0 1 1 1 1 1 0 1 1 8*
Özdemir 2001 1 0 1 1 1 0 1 0 1 1 7
Trials shown in Italics gave treatment outside suggested dose range. * indicates that the same method scores have been
given by PEDro reviewers. (*) indicates method score by PEDro reviewers where disagreement with our assessment
existed.
Figure 1. Effect of low level laser therapy on pain (mm on
a 100 mm VAS).
Health status Six trials measured change in health status,
and provided data that made it possible to calculate the
number of patients that improved their health status in
active LLLT groups and placebo laser groups (Table 5). In
one trial that used a lower dose than our suggested dose
range, no significant difference was registered between
groups (44% versus 47% with improved status; Basford et
al 1987). The remaining six trials used doses within our
suggested dose range. In one of them (Basford et al 1999),
the data showed a significant effect in favour of active laser
but the presentation of the data did not allow for
identification of  the number of patients who experienced
improvement. Five trials reported improved health status
for a total of 110 patients in the active LLLT groups versus
53 in the placebo groups. Health status remained
unchanged for 50 patients in the active LLLT-groups and
97 patients in the placebo groups. The pooled estimate of
the change of health status was significantly in favour of
active LLLT with a relative risk of 0.52 (95% CI 0.36 to
0.76) when calculated by a random effects model. The
results for health status are summarised in Figure 2.
Duration of pain relief Six trials with assumed optimal
treatment employed follow-up measurement of at least
three weeks. Four of these trials reported pain relief under
blinded conditions (Basford et al 1999, Götte et al 1995,
Gray et al 1994, Nivbrant and Friberg 1992). Two trials
with intensive, daily treatment regimens (Soriano and Rios
1998, Stelian et al 1992) reported pain reduction from
LLLT for four to six months, but evaluation in the follow-
up period was unblinded. 
Side effects and adverse reactions In terms of side effects,
six of the LLLT trials with optimal dose (Basford et al
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Table 5. List of included trials with data on treatment outcome.
First author No. of Condition Mean pain Mean pain Mean change Proportions Author’s test
patients (mm) before (mm) after in pain (mm) of patients of significance
treatment treatment improved
Basford 1987 81 Active 53 (missing data) 22/47 N.S.
Placebo 48 (missing data) 16/34
Jensen 1987 29 No separate pain score N.S.
(medication included)
Klein 1990 20 Active 40 23 17  N.S.
Placebo 44 28 16  
Stelian 1991 50 Active(Red) 65 33 32 p < 0.0001
Active(Infra) 72 32 40 (Before/ after)
Placebo 62 63 -1 
Nivbrant 1992 30 Active 67 44 23 p < 0.01
Placebo 58 54 4 (Before/ after)
Bulow 1994 29 Active 82 61 21 7/14 N.S.
Placebo 71 69 2 9/15
Gray 1994 55 Active 20/29 p < 0.001
Placebo 14/26 
Toya 1994 115 Active 43/59 p < 0.0001
Placebo 16/56 
Bertolucci 1995 32 Active 40 p < 0.01
Placebo 2
Gøtte 1995 40 Active * 69 42 27 13/20 “Significant”
Placebo* 70 68 2 2/20 (no p-value)
Conti 1997 20 Active 58 27 31 N.S.
Placebo 49 38 11
Soriano 1998 71 Active 79 (missing data) 27/38 p < 0.007
Placebo 81 (missing data) 12/33
Basford 1999 63 Active 35 17 18 p < 0.001
Placebo 37 33 4
Özdemir 2001 60 Active 77 24 53  p < 0.001
Placebo 73 68 5 
Randomised placebo-controlled trials where LLLT has been used for CJD. Outcome data are extracted from trial reports.
Trials shown in Italics gave treatment outside suggested dose range. *Visual estimates of data from graphs in trial report.
Blank boxes indicate missing data in trial report. N.S. = not statistically significant.
1999, Bulow et al 1994, Götte et al 1995, Nivbrant and
Friberg 1992, Soriano and Rios 1998, Stelian et al 1992)
explicitly stated in their report that no adverse effects were
observed. One trial reported an incident of transient
adverse effects for one patient in each group (Basford et al
1987).
Discussion
The results of this review were surprisingly unequivocal in
favour of active LLLT when dosage was titrated above the
suggested lower dose limit for reduction of inflammation.
In our opinion, many trial authors and reviewers have
investigated clinical effects without having a hypothesis of
which biological action they expect from LLLT. They have
often disregarded the fact that LLLT dose is affected by
physical and anatomical penetration characteristics.
Although we have tried to cater for these factors, it must be
remembered that our estimate range of laser penetration
(Table 1) is hypothetical. We currently lack hard data on
what biological effects laser causes at certain depths and
tissues in the human body. 
Perhaps the weakest point of this review is the
heterogeneity in treatment procedures and within the
patient sample. The latter is reflected by mean baseline
pain scores that ranged from 35 mm to 82 mm on VAS
(Table 5). In two trials it was explicitly stated that patients
were excluded if they experienced an acute episode of
exacerbation (Basford et al 1999, Klein and Eek 1990). For
the other trials, baseline pain was above 48 mm on the VAS.
Another issue that can partly explain heterogeneity in
results is that only some trials prohibited co-intervention by
anti-inflammatory drugs. The overall effect in trials that
explicitly allowed anti-inflammatory drugs was poorer than
those which did not allow for this co-intervention. This
adds support for our hypothesis that pain reduction from
LLLT is achieved through an anti-inflammatory action. 
The differences in numbers and frequencies of the
treatment sessions may also increase heterogeneity in
results. However, the majority of trials involved treatment
for two to four weeks, and only one trial (Toya et al 1994)
treated once and measured the immediate effect of LLLT.
We were in doubt whether this trial should be removed
from the calculations of improved health status.
The structures which contribute to neck pain or low back
pain are disputed, but both muscular and articular
structures seem to be involved. The majority of patients
with chronic spinal pain in our review had an x-ray
confirmed diagnosis of osteoarthritis (Basford et al 1999,
Ozdemir et al 2001, Soriano and Rios 1998). The presence
of inflammation, however variable in activity, is a cardinal
sign in osteoarthritis (Pelletier and Martel-Pelletier 2002).
For this reason, we decided to include these trials as
chronic joint disorders trials. 
We think that the inclusion of pain from the
temporomandibular joint is fairly uncontroversial. It is a
common condition and, like other chronic joint disorders, is
characterised by pain, synovial inflammation and
decreased range of motion (Rauhala et al 2000).
Assessing scientific evidence from clinical trials is always
a complex matter. We do agree that the methodological
quality of trials is important, and have assessed the trials
according to a widely accepted standard (the PEDro scale).
Fortunately, the included trials were all of acceptable
methodological quality, which made it unnecessary to
exclude any of them from our conclusion. Six of the trials
have been assessed by PEDro reviewers and confirm our
method scores. For one trial we found that partial blinding
was performed, which contradicts the PEDro review. In
addition, two other trials (Bertolucci and Grey 1995,
Stelian et al 1992) have previously been assessed by other
reviewers who found that they fulfilled more than half of
the quality criteria on the Jadad and Maastricht lists,
respectively. There is, however, genuine disagreement
between our method score and the score of a Swedish trial
(Nivbrant et al 1992) in another review (de Bie et al 1998).
This may be attributed to linguistic difficulties, or the fact
that two reports have been published from this trial.
There is some evidence that LLLT may inhibit fibroblast
activity (Loevschall and Arenholt-Bindslev 1994) when
dose exceeds 4 J. As the joint capsule is populated by
fibroblasts, future research is needed to clarify the matter
of optimal balance between biological effects such as
COX-2 inhibition and fibroblast activity. 
Laser dosage is a complex topic, and missing parameters
can give a misleading picture if they are not fully reported.
We have retrieved the missing laser parameters by getting
specifications from the manufacturers of all the lasers used
in the included trials and we have recalculated all power
densities, dose per treatment sessions and weekly doses.
However, it is a weakness that testing and calibration of
laser output was only performed in two of the clinical trials
(Basford et al 1999, Bulow et al 1994). 
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Figure 2. Effect of low level laser therapy on health status
(Relative risk of not improving)
In five of six LLLT trials with follow-up, pain reduction
remained significant for three weeks, and unblinded
follow-up suggested significant pain reduction for up to six
months (Stelian et al 1992).
The literature on LLLT is full of conflicting reports, and we
believe that much of this is caused by the lack of dosage
consensus. One large, well-designed trial found no effect
from LLLT on ankle sprains (de Bie et al 1998). In our
opinion, the poor results may have been caused by
insufficient irradiation, because only a single 1 cm2 point
of the swollen joint capsule was treated by LLLT. In a
recent review on LLLT effectiveness (Brosseau et al 2000),
results for osteoarthritis were conflicting. This review
lacked procedural assessment of the laser exposure
technique, and dose analysis was not used to adjust for
differences in energy loss for each anatomical location. In
addition, our literature search is more recent and extensive
and includes two more trials on osteoarthritis of the knee
(Götte et al 1995, Nivbrant and Friberg 1992), in addition
to trials with spinal and temporomandibular joint disorders.
Conclusion
Although the heterogeneity of the trial results calls for
caution in interpretation, LLLT seemed to be effective in
reducing pain from chronic joint disorders. The hypothesis
that LLLT acts through a dose-specific anti-inflammatory
effect in the irradiated joint capsule is a potential
explanation of the positive results. This hypothesis needs to
be verified or refuted in studies where outcome measures
of inflammatory activity are used. More and larger trials
are needed to precisely determine optimal treatment
procedures for LLLT and possible interaction with other
therapies for chronic joint disorders.
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